1. Home
  2. KODK vs LBRX Comparison

KODK vs LBRX Comparison

Compare KODK & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eastman Kodak Company

KODK

Eastman Kodak Company

N/A

Current Price

$7.55

Market Cap

739.4M

ML Signal

N/A

LBRX

LB Pharmaceuticals Inc

N/A

Current Price

$24.75

Market Cap

602.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KODK
LBRX
Founded
1880
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
739.4M
602.6M
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
KODK
LBRX
Price
$7.55
$24.75
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$49.00
AVG Volume (30 Days)
603.2K
145.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
34.33
N/A
EPS
N/A
N/A
Revenue
$4,114,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.93
$13.40
52 Week High
$9.96
$24.95

Technical Indicators

Market Signals
Indicator
KODK
LBRX
Relative Strength Index (RSI) 48.60 58.41
Support Level $6.24 $22.48
Resistance Level $7.88 $24.70
Average True Range (ATR) 0.29 1.32
MACD 0.02 -0.03
Stochastic Oscillator 51.32 84.65

Price Performance

Historical Comparison
KODK
LBRX

About KODK Eastman Kodak Company

Eastman Kodak Co is a United States-based company. It operates through several business segments; Print, Brand, and Advanced Materials and Chemicals. The Print segment which derives the majority of revenue includes products like digital offset plate offerings and computer-to-plate imaging solutions, high-quality digital printing solutions using electrically charged toner-based technology, production press systems, consumables, inkjet components, software and services. Geographically, the company generates revenue from the United States, Canada, Europe, Middle East and Africa, Asia Pacific, and Latin America.

About LBRX LB Pharmaceuticals Inc

LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.

Share on Social Networks: